Novartis has reported positive outcomes from the multicentre Phase IIIB APPULSE-PNH study of oral Fabhalta (iptacopan).

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

The relationship between neurodegenerative conditions and late-life mood disorders (LLMDs) is largely unexplored.

MSD has begun the randomised MOBILIZE-1 Phase III trial to assess the investigational quadrivalent vaccine, V181.

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in ...

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Johnson & Johnson (J&J) has reported that Tremfya (guselkumab) minimised the symptoms and signs of active psoriatic arthritis ...

At the CTO West Coast conference, experts discussed the future of oncology clinical trials and key themes surrounding them.

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

HepaRegeniX has begun dosing subjects in a Phase Ib trial of HRX-215 in subjects undergoing partial liver resection due to ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

Experts say clinicians struggle for time to support clinical studies, limiting the scope of progress from regulatory revisions.